Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902219-25-000435
Filing Date
2025-11-12
Accepted
2025-11-12 09:33:32
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10641
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 4407
  Complete submission text file 0000902219-25-000435.txt   17187
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 0000

Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Subject) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90538 | Film No.: 251469833
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)